血浆髓过氧化酶与冠心病的临床研究  

Clinical implications of myeloperoxidase in patients with coronary artery disease

作　　者：于宗良[1] 姚永良[2] 谷惠敏[1] 赵志强[1] 顾明[1] 朱建中[1] 冯振勤[1] 许浩军[1] 汪强[1] 李联邦[1] 孙学明[1] 周伟伟[1] 宋建平[3] 杨向军[3] 

机构地区：[1]江苏大学附属昆山市第一人民医院心内科,昆山市215300 [2]江苏大学附属昆山市第一人民医院检验科,昆山市215300 [3]苏州大学附属第一医院

出　　处：《中国心血管病研究》2008年第9期668-669,共2页Chinese Journal of Cardiovascular Research

摘　　要：目的探讨血浆髓过氧化酶(MPO)与冠状动脉粥样硬化性心脏病(CAD)的临床关系。方法利用酶联免疫法测定78例CAD患者血浆MPO、C反应蛋白(CRP)和白细胞(WBC)值,并与46例非CAD患者进行对比。结果CAD中急性冠脉综合征(ACS)组患者血浆髓过氧化酶水平显著增高,且与CRP、WBC呈正相关;而稳定型心绞痛(SAP)组MPO水平与对照组差异无统计学意义。结论血浆MPO水平可以预测冠心病ACS的危险性,对严重心血管事件的发生有一定的预警作用。Objective To study clinical implications of Myeloperoxidase （MPO） in patients with coronary artery disease. Methods Plasma levels of MPO, C-reactive protein （CRP） and WBC were determinated in 78 patients with coronary artery disease, and 46 normal controls. The clinical relations between MPO, CRP and WBC were studied in each group. Results The plasma levels of MPO were significant higher in CAD patients with acute coronary syndromes （ACS）than those of stable angina pectoris and the controls. MPO had positive correlation with CRP and WBC in ACS patients. Conclusion Serum levels of MPO may be useful indictors in evaluating and predicting patients with ACS.

关 键 词：髓过氧化酶 冠状动脉疾病 急性冠脉综合征 

分 类 号：R541.4[医药卫生—心血管疾病]